Visfatin is also under investigation as a potential biomarker in various types of cancers, as it is upregulated in tissue or plasma of patients with cancers such as oral squamous cell carcinoma, pancreatic ductal adenocarcinoma, breast cancer and thyroid malignancy based on a pan-cancer scale [42]. This evidence concerns the gene NAMPT and cancer.